3104965-33-2
3104965-33-2
Chemical Structure
BP79
- CAS No.: 3104965-33-2
- Formula:C10H8Cl2N2O2
- Molecular Weight:259.09
InChIKey: GZMJWYPHCVXRNQ-ARJAWSKDSA-N
SMILES: NC(/C=C\C(NC1=CC(Cl)=C(C=C1)Cl)=O)=O
Biological Activity: BP79 is a potent TSLP receptor inhibitor. BP79 disrupts TSLP-mediated ternary complex formation, blocks TSLPR-IL7Rα co-localization, binds and stabilizes TSLPR, and inhibits phosphorylated STAT3/6. BP79 suppresses immune cell infiltration, secretion of IL-13, IL-4. BP79 can be used for the research of inflammation diseases, such as atopic dermatitis, allergic asthma, and allergic rhinitis[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
BP79 | BP79 is a potent TSLP receptor inhibitor. BP79 disrupts TSLP-mediated ternary complex formation, blocks TSLPR-IL7Rα co-localization, binds and stabilizes TSLPR, and inhibits phosphorylated STAT3/6. BP79 suppresses immune cell infiltration, secretion of IL-13, IL-4. BP79 can be used for the research of inflammation diseases, such as atopic dermatitis, allergic asthma, and allergic rhinitis. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Adhikary PP, et al. Disrupting TSLP-TSLP receptor interactions via putative small molecule inhibitors yields a novel and efficient treatment option for atopic diseases. EMBO Mol Med. 2024;16(7):1630-1656. [Content Brief]
-
[2]. Christopher Hoang. The development of small molecule inhibitors of thymic stromal lymphopoietin signaling for the treatment of atopic dermatitis. \t
University of British Columbia. December 2023. -
[3]. Sarah Hedtrich, et al. N1-(3,4-dichlorophenyl)maleamide derivatives and the use thereof in the treatment of inflammatory disorders. WO2025213277A1. 2025-10-16.
